Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Major Program

Supportive Care and Symptom Management

NCI Community Oncology Research Program

Research Group

Community Oncology and Prevention Trials

Status

Active, not recruiting

NCT ID

NCT04939597

This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.

Intervention

Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration

Condition

Central Nervous System Carcinoma

Investigators

Nadia N Laack, Nadia N. Laack

See list of participating sites